Risk of gallbladder or biliary disease is associated with use of GLP-1 agonists.5
With GLP-1 agonists, the rate of weight loss may be particularly rapid during the first 12 to 16 weeks of treatment.7,8
Prescribing information for many GLP-1 agonists includes warnings of the risk of gallbladder disease, including cholelithiasis and cholecystitis.9-15